Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

OBJECTIVES: Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin. We aimed to evaluate efficacy and safety of 600 versus 800 mg of efavirenz in tuberculosis/HIV patients using rifampicin. DESIGN: We conducted an open label, multicentre, randomi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Biomed Res Int
Prif Awduron: Xavier, Mariana S., Trajman, Anete, Schmaltz, Carolina A. S., Sant'anna, Flavia M., Maia, Ivan R., Hadad, David J., do Brasil, Pedro Emmanuel A. A., Rolla, Valeria
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6354140/
https://ncbi.nlm.nih.gov/pubmed/30792988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9231835
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg